Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Theriva Biologics Inc (TOVX)

Theriva Biologics Inc (TOVX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,512
  • Shares Outstanding, K 8,187
  • Annual Sales, $ 0 K
  • Annual Income, $ -25,650 K
  • EBIT $ -20 M
  • EBITDA $ -14 M
  • 60-Month Beta 0.85
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.08
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -13.86
  • Most Recent Earnings $-1.55 on 05/14/25
  • Next Earnings Date 08/12/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4020 +7.84%
on 05/28/25
0.5466 -20.69%
on 06/11/25
-0.0215 (-4.73%)
since 05/23/25
3-Month
0.4020 +7.84%
on 05/28/25
1.5000 -71.10%
on 04/25/25
-0.7695 (-63.97%)
since 03/24/25
52-Week
0.4020 +7.84%
on 05/28/25
7.3725 -94.12%
on 07/18/24
-5.6815 (-92.91%)
since 06/24/24

Most Recent Stories

More News
Therivaâ„¢ Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review Topline Data from the VIRAGE Phase 2b Trial of VCN-01 in Metastatic Pancreatic Cancer

TOVX : 0.4387 (+2.26%)
Therivaâ„¢ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results

TOVX : 0.4387 (+2.26%)
Theriva Biologics Announces Closing of $7.5 Million Public Offering

TOVX : 0.4387 (+2.26%)
Theriva Biologics Announces Pricing of $7.5 Million Public Offering

TOVX : 0.4387 (+2.26%)
Therivaâ„¢ Biologics Announces Primary Endpoints for Efficacy and Safety Achieved in VIRAGE Phase 2b Clinical Trial of VCN-01 with Gemcitabine/nab-Paclitaxel in Newly-Diagnosed Metastatic Pancreatic Cancer Patients

TOVX : 0.4387 (+2.26%)
Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

TOVX : 0.4387 (+2.26%)
Theriva™ Biologics Announces Positive Outcomes from the Second Meeting of the Independent Data Monitoring Committee for VIRAGE, the Company’s Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal...

TOVX : 0.4387 (+2.26%)
Therivaâ„¢ Biologics to Present at the 2025 NeauxCancer Conference

TOVX : 0.4387 (+2.26%)
Q1 Virtual Investor Summit: On-Demand Presentations Now Live

NEW YORK, NY / ACCESS Newswire / March 18, 2025 / The Investor Summit is excited to announce that presentations from Q1 Investor Summit are now available for on-demand viewing. Attendees and investors...

SNANF : 0.3261 (+0.22%)
BRNS : 0.9026 (+1.53%)
FEMY : 0.9074 (+0.71%)
PERF : 2.14 (+3.38%)
DRTS : 3.02 (+1.17%)
GIFT : 1.4850 (-0.34%)
ROYIF : 0.0520 (-19.00%)
ZCAR : 0.5100 (-4.28%)
CLNN : 4.22 (+2.82%)
MIND : 8.37 (-3.13%)
PYPD : 3.61 (-1.90%)
TOVX : 0.4387 (+2.26%)
Therivaâ„¢ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results

TOVX : 0.4387 (+2.26%)

Business Summary

Theriva Biologics Inc. is a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need. The Company's lead candidate includes VCN-01, SYN-004 and SYN-020. Theriva Biologics Inc., formerly known as Synthetic Biologics Inc., is based in ROCKVILLE,...

See More

Key Turning Points

3rd Resistance Point 0.4579
2nd Resistance Point 0.4514
1st Resistance Point 0.4402
Last Price 0.4387
1st Support Level 0.4225
2nd Support Level 0.4160
3rd Support Level 0.4048

See More

52-Week High 7.3725
Fibonacci 61.8% 4.7098
Fibonacci 50% 3.8872
Fibonacci 38.2% 3.0647
Last Price 0.4387
52-Week Low 0.4020

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
OSZAR »